[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363803-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363803-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","quantitative-18fpsma-1007-pet-in-treatment-response-monitoring-of-brain-metastases-from-non-small-cell-lung-cancer","Quantitative [18F]PSMA-1007 PET in Treatment Response Monitoring of Brain Metastases from Non-small Cell Lung Cancer","","Quantitative dynamic dual-time-point [18F]PSMA-1007 PET/CT was used to evaluate tracer uptake and treatment response in brain metastases from non-small cell lung cancer. Eleven patients underwent imaging before and after stereotactic radiosurgery, with a subset completing both examinations. Image-derived input functions from internal carotid arteries and Patlak pharmacokinetic modelling produced influx constants, while SUV, biological tumour volume, and heterogeneity were quantified. Post-therapy changes highlighted reductions across kinetic, uptake, heterogeneity, and volume measures.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/quantitative-18fpsma-1007-pet-in-treatment-response-monitoring-of-brain-metastases-from-non-small-cell-lung-cancer/363803/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/quantitative-18fpsma-1007-pet-in-treatment-response-monitoring-of-brain-metastases-from-non-small-cell-lung-cancer/363803.png","ImageObject",300,407,{"name":42,"@type":43},"Guten tag","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of using quantitative [18F]PSMA-1007 PET in this study?","Question",{"text":63,"@type":64},"The study investigates quantitative [18F]PSMA-1007 uptake and treatment response in brain metastases from non-small cell lung cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were PET parameters derived and which measures were assessed?",{"text":68,"@type":64},"Input functions were extracted from the internal carotid arteries and Patlak modelling was used to calculate the influx constant (Ki). SUV, biological tumour volume (BTV), and tumour heterogeneity via coefficient of variance (CoV) were also assessed.",{"name":70,"@type":61,"acceptedAnswer":71},"What changes were observed after stereotactic radiosurgery (SRS)?",{"text":72,"@type":64},"After SRS, Ki, SUVpeak, CoV, and BTV all decreased, with the largest reduction reported for BTV (71%), supporting PET’s potential for monitoring treatment response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363803,1790459868,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","Molecular Imaging and Biology (2026) 28:438–448 [https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1307-026-02104-w  \nQuantitative [ 18 F]PSMA‑1007 PET in Treatment Response Monitoring of Brain Metastases from Non‑small Cell Lung Cancer  \nElisabeth Kirkeby Lysvik1,2 · Andreas Julius Tulipan3 · Vilde Drageset Haakensen2,4 · Mona‑Elisabeth R. Revheim2,5 · Kyrre Eeg Emblem1 · Trine Hjørnevik1,2  \nReceived: 14 November 2025 / Revised: 26 February 2026 / Accepted: 14 April 2026 / Published online: 23 April 2026 © The Author(s) 2026  \nAbstract  \nPurpose Prostate-specific membrane antigen (PSMA) is expressed in several solid tumours, including brain metastases (BMs) from lung cancer. We investigated quantitative [ 18F]PSMA-1007 uptake and treatment response in BMs of patients with non-small cell lung cancer (NSCLC) .  \nProcedures Eleven patients with BM of NSCLC underwent 95-min dual-time-point dynamic [ 18F]PSMA-1007 PET/CT anda whole-body static scan before and after stereotactic radiosurgery (SRS) with a median dose of 20 Gy (range: 8–25 Gy) given in a median of 1 fraction (range: 1–3) . Seven patients completed both exams. Image-derived input functions were extracted from the internal carotid arteries, and pharmacokinetic analysis using Patlak modelling yielded the influx constant (Ki). Standardised uptake value (SUV), biological tumour volume (BTV) and tumour heterogeneity using the coefficient of variance (CoV) were assessed.  \nResults [ 18F]PSMA-1007 PET showed uptake in the first exam in BMs and primary lung tumour in all patients. Significant inter-patient and intra-lesion heterogeneity in tracer uptake was observed in BMs with median Ki of 0.005 ml/ccm/min (range: 0.003–0.018 ml/ccm/min), SUVpeak of 4.2 g/ml (range: 0.4–34.4 g/ml), CoV of 0.36 (range 0.06–0.85) and BTV of 2.35 ml (range 0.03–22.29 ml). After SRS, reductions in Ki (37%), SUVpeak (50%), CoV (24%) and BTV (71%) were noted. Median SUVpeak in the lungs were 6.1 g/ml (range: 3.2–13.6 g/ml) at the initial exam and 6.3 g/ml (range: 3.8–11.8 g/ml) at the second exam.  \nConclusion [18F]PSMA-1007 PET is a promising diagnostic tool for BMs from NSCLC. The uptake and heterogeneity, along with the marked reduction post-therapy, highlights its potential for monitoring treatment response.  \nTrial registration [Clinicaltrials.gov](Clinicaltrials.gov), NCT03951142. Registered 5 October 2019, [https://clinicaltrials.gov/ct2/show/NCT03](https://clinicaltrials.gov/ct2/show/NCT03)[ ](https://clinicaltrials.gov/ct2/show/NCT03)951142. EudraCT no 2018-003229-27. Registered 26 February 2019, [https://www.clinicaltrialsregister.eu/ctr-search/trial/](https://www.clinicaltrialsregister.eu/ctr-search/trial/)[ ](https://www.clinicaltrialsregister.eu/ctr-search/trial/)2018-003229-27/NO.  \nKeywords Dynamic PET · PSMA · Lung cancer · Brain metastasis · Patlak  \n* Elisabeth Kirkeby Lysvik[eliski@uio.no](eliski@uio.no)  \n1 Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Building 20, Gaustad Sykehus, Sognsvannveien 21, 0372 Oslo, Norway  \n2 Institute of Clinical Medicine, University of Oslo, Oslo, Norway  \n3 Department of Nuclear Medicine, Oslo University Hospital, Oslo, Norway  \n4 Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway  \n5 The Intervention Centre, Division of Technology and Innovation, Oslo University Hospital, Oslo, Norway  \nIntroduction  \nNon-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths and frequently gives rise to brain metastases (BMs), with 15–20% of NSCLC patients presenting with BM at diagnosis and 40% developing BM over the course of their disease [1] . Patients receive various treatments, including surgery, radiotherapy, chemotherapy, immunotherapy and molecular targeted therapy, alone or in combination. Targeted therapy has significantly improved outcomes in a proportion of patients with advanced NSCLC [2–4] . Further resea","cbCaiiyZ4h17coJp","https://ap.wps.com/l/cbCaiiyZ4h17coJp","pdf",2087139,11,"English","# Abstract\n## Purpose\n## Procedures and Analysis\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the purpose of using quantitative [18F]PSMA-1007 PET in this study?\",\"answer\":\"The study investigates quantitative [18F]PSMA-1007 uptake and treatment response in brain metastases from non-small cell lung cancer.\"},{\"question\":\"How were PET parameters derived and which measures were assessed?\",\"answer\":\"Input functions were extracted from the internal carotid arteries and Patlak modelling was used to calculate the influx constant (Ki). SUV, biological tumour volume (BTV), and tumour heterogeneity via coefficient of variance (CoV) were also assessed.\"},{\"question\":\"What changes were observed after stereotactic radiosurgery (SRS)?\",\"answer\":\"After SRS, Ki, SUVpeak, CoV, and BTV all decreased, with the largest reduction reported for BTV (71%), supporting PET’s potential for monitoring treatment response.\"}]","Quantitative [18F]PSMA-1007 PET in Treatment Response Monitoring of Brain Metastases from Non-small Cell Lung Cancer | PDF",1790153251,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82b67db128bc567a0996402c01863a70.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78b9b0f3c653630958e748797037b8ab.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff8f92394744d7717d865990aa6703e1.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca99ef59afbf9a614c91c1a3f78d5a1d.webp",980,1301]